{
  "approved_at_utc": null,
  "subreddit": "stocks",
  "selftext": "Celltrion is a 32 billion market cap biotech leader developing monoclonal anti-bodies for a variety of indications, including COVID-19 (regdanvimab) and a whole mess of other inflammatory diseases such as RA and Crohn's disease.   They're going up against Abbvie with a biosimilar for Humira called Yuflyma that was recently shown to be equivalent and should role out in Europe soon.  They've also got a biosimilar for Remicade called Remsima (Inflectra in the USA) that's already on the market.  \n\nThe news now is that Celltrion is partnering with 180 Life Sciences (ATNF) to supply drugs in 180's clinical trials.\n\n[https://finance.yahoo.com/news/celltrion-healthcare-180-life-sciences-120000932.html](https://finance.yahoo.com/news/celltrion-healthcare-180-life-sciences-120000932.html)\n\n&#x200B;\n\nOn the face of it, this is not that interesting.  But as an long-term 180 Life Sciences ($ATNF) bull, I assure you, it's very interesting.  The founders of ATNF are the guys that originally discovered Remicade and Humira.  They're carrying all sorts of trade-secrets around in their heads that could enhance Celltrion's biosimilars program as it accelerates into manufacturing in China.  On top of that, ATNF has a very attractive patent portfolio in its own right and is in the middle of running a handful of clinical trials.  Reading between the lines, this simple supply deal starts to smell a lot more like a potential merger, especially since ATNF's latest clinical trials will be using Celltrion's drugs.\n\n&#x200B;\n\nCelltrion is traded on KSE (Korean Stock Exchange) and ATNF is traded on the Nasdaq.  \n\n&#x200B;\n\nDisclaimer: I am not a financial advisor and this is not financial advice.",
  "author_fullname": "t2_9zyvly0z",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "Celltrion and 180 Life Sciences",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/stocks",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": null,
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_psu0a8",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.94,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 59,
  "total_awards_received": 0,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": null,
  "can_mod_post": false,
  "score": 59,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": false,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1632264006,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.stocks",
  "allow_live_comments": false,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Celltrion is a 32 billion market cap biotech leader developing monoclonal anti-bodies for a variety of indications, including COVID-19 (regdanvimab) and a whole mess of other inflammatory diseases such as RA and Crohn&#39;s disease.   They&#39;re going up against Abbvie with a biosimilar for Humira called Yuflyma that was recently shown to be equivalent and should role out in Europe soon.  They&#39;ve also got a biosimilar for Remicade called Remsima (Inflectra in the USA) that&#39;s already on the market.  </p>\n\n<p>The news now is that Celltrion is partnering with 180 Life Sciences (ATNF) to supply drugs in 180&#39;s clinical trials.</p>\n\n<p><a href=\"https://finance.yahoo.com/news/celltrion-healthcare-180-life-sciences-120000932.html\">https://finance.yahoo.com/news/celltrion-healthcare-180-life-sciences-120000932.html</a></p>\n\n<p>&#x200B;</p>\n\n<p>On the face of it, this is not that interesting.  But as an long-term 180 Life Sciences ($ATNF) bull, I assure you, it&#39;s very interesting.  The founders of ATNF are the guys that originally discovered Remicade and Humira.  They&#39;re carrying all sorts of trade-secrets around in their heads that could enhance Celltrion&#39;s biosimilars program as it accelerates into manufacturing in China.  On top of that, ATNF has a very attractive patent portfolio in its own right and is in the middle of running a handful of clinical trials.  Reading between the lines, this simple supply deal starts to smell a lot more like a potential merger, especially since ATNF&#39;s latest clinical trials will be using Celltrion&#39;s drugs.</p>\n\n<p>&#x200B;</p>\n\n<p>Celltrion is traded on KSE (Korean Stock Exchange) and ATNF is traded on the Nasdaq.  </p>\n\n<p>&#x200B;</p>\n\n<p>Disclaimer: I am not a financial advisor and this is not financial advice.</p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qjfk",
  "author_is_blocked": false,
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "psu0a8",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "RelationPure306",
  "discussion_type": null,
  "num_comments": 15,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/stocks/comments/psu0a8/celltrion_and_180_life_sciences/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/stocks/comments/psu0a8/celltrion_and_180_life_sciences/",
  "subreddit_subscribers": 3059601,
  "created_utc": 1632306586,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1632264006,
  "the_new_excerpt": "Celltrion is a 32 billion market cap biotech leader developing monoclonal\nanti-bodies for a variety of indications, including COVID-19 (regdanvimab) and a\nwhole mess of other inflammatory diseases such as RA and Crohn's disease.\nThey're going up against Abbvie with a biosimilar for Humira called…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "Celltrion社は時価総額320億円のバイオテック企業で、様々な分野のモノクローナル抗体を開発しています。\nCOVID-19（レグダンビマブ）をはじめとする様々な適応症のモノクローナル抗体を開発しています。\nCOVID-19（レグダンビマブ）をはじめ、RAやクローン病などの炎症性疾患の治療薬を開発しています。\nアッヴィに対抗して、ヒュミラのバイオシミラーである...",
      "title": "セルトリオンと180ライフサイエンス"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "Celltrion是一家市值320亿美元的生物技术领先企业，为各种适应症开发单克隆\n适应症的单克隆抗体，包括COVID-19 (regdanvimab) 和\n包括COVID-19（regdanvimab）和其他炎症性疾病，如RA和Crohn's疾病的整个混乱。\n他们正在与艾伯维公司对抗，推出名为Humira的生物仿制药。",
      "title": "Celltrion和180生命科学公司"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "Celltrion是一家市值320億美元的生物技術領先企業，爲各種適應症開發單克隆\n適應症的單克隆抗體，包括COVID-19 (regdanvimab) 和\n包括COVID-19（regdanvimab）和其他炎症性疾病，如RA和Crohn's疾病的整個混亂。\n他們正在與艾伯維公司對抗，推出名爲Humira的生物仿製藥。",
      "title": "Celltrion和180生命科學公司"
    }
  ],
  "source_updated_at": 1632476400531
}